Zevra Therapeutics announced the commencement of a proposed underwritten public offering of its common stock. All shares of common stock to be sold in the proposed offering will be sold by Zevra. Cantor and William Blair are acting as joint book-running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics Announces Proposed Public Offering of Common Stock
- Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference
- Zevra Therapeutics price target raised to $18 from $15 at H.C. Wainwright
- FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
- FDA Genetic Metabolic Diseases Advisory Committee holds a meeting